Mezagitamab (TAK-079) is an IgG1?? monoclonal antibody targeting CD38. This antibody facilitates the depletion of tumor cells that express CD38 via mechanisms of antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). It is currently being investigated for its therapeutic potential in treating conditions such as relapsed/refractory multiple myeloma (RRMM) and idiopathic thrombocytopenic purpura (ITP), demonstrating significant relevance in clinical research settings focused on hematologic malignancies and autoimmune disorders.
Mezagitamab (TAK-079) is an IgG1?? monoclonal antibody targeting CD38. This antibody facilitates the depletion of tumor cells that express CD38 via mechanisms of antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). It is currently being investigated for its therapeutic potential in treating conditions such as relapsed/refractory multiple myeloma (RRMM) and idiopathic thrombocytopenic purpura (ITP), demonstrating significant relevance in clinical research settings focused on hematologic malignancies and autoimmune disorders.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
